Department of Surgery, University of Miami Miller School of Medicine, FL, USA.
Ann Surg. 2011 Sep;254(3):527-37; discussion 537-8. doi: 10.1097/SLA.0b013e31822ca66f.
To compare outcomes for patients with hepatocellular carcinoma (HCC) treated with either liver resection or transplantation.
A retrospective, single-institution analysis of 413 HCC patients from 1999 to 2009.
A total of 413 patients with HCC underwent surgical resection (n = 106) and transplantation (n = 270) or were listed without receiving transplantation (n = 37). Excluding transplanted patients with incidental tumors (n = 50), 257 patients with suspected HCC were listed with the intent to transplant (ITT). The median diameter of the largest tumor by radiography was 6.0 cm in resected, 3.0 cm in transplanted, and 3.4 cm in the listed-but-not-transplanted patients. Median time to transplant was 48 days. Recurrence rates were 19.8% for resection and 12.1% for all ITT patients. Overall, patient survival for resection versus ITT patients was similar (5-year survival of 53.0% vs 52.0%, not significant). However, for HCC patients with model end-stage liver disease (MELD) scores less than 10 and who radiologically met Milan or UCSF (University of California, San Francisco) criteria, 1-year and 5-year survival rates were significantly improved in resected patients. For patients with MELD score less than 10 and who met Milan criteria, 1-year and 5-year survival were 92.0% and 63.0% for resection (n = 26) versus 83.0% and 41.0% for ITT (n = 73, P = 0.036). For those with MELD score less than 10 and met UCSF criteria, 1-year and 5-year survival was 94.0% and 62.0% for resection (n = 33) versus 81.0% and 40.0% for ITT (n = 78, P = 0.027).
Among known HCC patients with preserved liver function, resection was associated with superior patient survival versus transplantation. These results suggest that surgical resection should remain the first line therapy for patients with HCC and compensated liver function who are candidates for resection.
比较肝癌(HCC)患者接受肝切除术或肝移植治疗的结果。
对 1999 年至 2009 年期间的 413 例 HCC 患者进行回顾性单机构分析。
共有 413 例 HCC 患者接受了肝切除术(n=106)和肝移植(n=270),或未接受肝移植(n=37)。排除意外肿瘤的移植患者(n=50),257 例疑似 HCC 患者被列入移植名单(意向移植)。影像学最大肿瘤直径在切除组为 6.0cm,移植组为 3.0cm,未移植组为 3.4cm。中位移植时间为 48 天。切除组的复发率为 19.8%,所有意向移植组的复发率为 12.1%。总体而言,切除组与意向移植组患者的生存率相似(5 年生存率分别为 53.0%和 52.0%,无显著性差异)。然而,对于 MELD 评分小于 10 且影像学符合米兰或 UCSF(加利福尼亚大学旧金山分校)标准的 HCC 患者,切除组患者的 1 年和 5 年生存率显著提高。对于 MELD 评分小于 10 且符合米兰标准的患者,切除组的 1 年和 5 年生存率分别为 92.0%和 63.0%(n=26),意向移植组分别为 83.0%和 41.0%(n=73,P=0.036)。对于 MELD 评分小于 10 且符合 UCSF 标准的患者,切除组的 1 年和 5 年生存率分别为 94.0%和 62.0%(n=33),意向移植组分别为 81.0%和 40.0%(n=78,P=0.027)。
在已知具有保留肝功能的 HCC 患者中,与移植相比,切除与患者生存率的提高相关。这些结果表明,对于符合切除条件且肝功能代偿的 HCC 患者,手术切除应仍然是首选治疗方法。